AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31706460 — intervention group
Group type: EXPERIMENTAL
Intervention: Abriendo Caminos Program (6 weekly, 2-hour group workshops on nutrition education, family wellness, and physical activity)
Number of subjects: 500
Study 31706460 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated-attention control group
Number of subjects: 500
Study 27569864 — intervention group
Group type: EXPERIMENTAL
Intervention: INDIVIDUO intervention group (IG)
Number of subjects: 94
Study 27569864 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 94
Study 25733636 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite food (measured by Food Pmax) vs Baby Einstein-Baby MacDonald shows (study 1)
Number of subjects: 57
Study 25733636 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite food (measured by Food Pmax) vs bubbles (study 2)
Number of subjects: 57
Study 24323139 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (independent apartments)
Number of subjects: 0
Study 24323139 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (congregate residence)
Number of subjects: 0
Study 24323139 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 22688849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon/ribavirin lead-in therapy
Number of subjects: 834
Study 22688849 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 834
Study 19223704 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surgical treatment
Number of subjects: 49
Study 19223704 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 49
Study 17215033 — intervention group
Group type: EXPERIMENTAL
Intervention: Codfish digested at pH 2.0
Number of subjects: 0
Study 17215033 — intervention group
Group type: EXPERIMENTAL
Intervention: Codfish digested at pH 3.0
Number of subjects: 0
Study 17215033 — intervention group
Group type: COMPARATOR
Intervention: Undigested codfish extracts
Number of subjects: 0
Study 15902303 — intervention group
Group type: EXPERIMENTAL
Intervention: UM‐CLL B cells
Number of subjects: 0
Study 15902303 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐CLL B cells
Number of subjects: 0
Study 15902303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutated nonautoreactive CLL antibody sequences reverted to germline counterparts
Number of subjects: 0
Study 12581508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium aerosol (4 mg) inhaled 30 minutes before allergen challenge
Number of subjects: 10
Study 9497185 — intervention group
Group type: EXPERIMENTAL
Intervention: lactoovovegetarian diet
Number of subjects: 21
Study 9497185 — intervention group
Group type: COMPARATOR
Intervention: nonvegetarian diet
Number of subjects: 21
Study 9873197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of GH
Number of subjects: 23
Study 9873197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous infusion and bolus injections of GH
Number of subjects: 23
Study 9873197 — intervention group
Group type: COMPARATOR
Intervention: Bolus injections of GH
Number of subjects: 23
Study 9873197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous (s.c.) infusion of GH
Number of subjects: 23
Study 9873197 — intervention group
Group type: COMPARATOR
Intervention: Daily s.c. injections of GH
Number of subjects: 23
Study 9873197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GH pattern
Number of subjects: 23
Study 1914718 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA irrigation (acetate: 60 mmol/liter; propionate: 30 mmol/liter; N-butyrate: 40 mmol/liter)
Number of subjects: 13
Study 1914718 — intervention group
Group type: COMPARATOR
Intervention: Isotonic NaCl
Number of subjects: 13
Study 6356898 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg (single dose and three times a day for three days)
Number of subjects: 11
Study 6356898 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg (single dose and twice a day for three days)
Number of subjects: 11
Study 6356898 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg three times a day
Number of subjects: 11
Study 6356898 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg twice a day
Number of subjects: 11
Study 29608340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (4 weekly 1-hour group-based exercise classes targeting strength training, endurance, balance, and flexibility)
Number of subjects: 572
Study 29608340 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution retraining session (1-hour session teaching that aging does not mean one inevitably becomes sedentary)
Number of subjects: 572
Study 29608340 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic health education)
Number of subjects: 572
Study 30205379 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day plus PTX (400 mg b.i.d.)
Number of subjects: 80
Study 30205379 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg/day plus placebo
Number of subjects: 80
Study 25823668 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 400 mg every 4 weeks
Number of subjects: 0
Study 25823668 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 800 mg every 8 weeks
Number of subjects: 0
Study 23298410 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus Dermagraft® (bioengineered ECM containing living fibroblasts)
Number of subjects: 0
Study 23298410 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus Oasis® (ECM devoid of living cells)
Number of subjects: 0
Study 23298410 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 21450063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined implementation (CI) strategy
Number of subjects: 45
Study 21450063 — intervention group
Group type: COMPARATOR
Intervention: Usual educational (ED) strategy
Number of subjects: 45
Study 18694831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 69
Study 18694831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*3 allele
Number of subjects: 69
Study 18694831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*3
Number of subjects: 69
Study 18694831 — intervention group
Group type: COMPARATOR
Intervention: CYP2C8*1
Number of subjects: 69
Study 16880097 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT‐proBNP levels in patients with LV systolic dysfunction (LVEF < 55%)
Number of subjects: 191
Study 16880097 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT‐proBNP levels in patients with normal LV systolic function (LVEF >= 55%)
Number of subjects: 191
Study 16880097 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n = 43)
Number of subjects: 191
Study 14600932 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stress during myocardial perfusion SPECT study
Number of subjects: 46
Study 10831560 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg recombinant human chorionic gonadotrophin (rHCG; Ovidrel)
Number of subjects: 84
Study 10831560 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU urinary HCG (uHCG; Profasi)
Number of subjects: 84
Study 10831560 — intervention group
Group type: EXPERIMENTAL
Intervention: rHCG
Number of subjects: 84
Study 10831560 — intervention group
Group type: COMPARATOR
Intervention: uHCG
Number of subjects: 84
Study 8669268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg a day
Number of subjects: 30
Study 8669268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg a day (combined with Cetirizine)
Number of subjects: 30
Study 8669268 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Rhinocort Aqua)
Number of subjects: 30
Study 8669268 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (Allergodil nasal spray)
Number of subjects: 30
Study 1611372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for acute cough
Number of subjects: 3500
Study 1611372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for acute vomiting
Number of subjects: 3500
Study 1611372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for itchy rash
Number of subjects: 3500
Study 1611372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for recurrent wheezy chest
Number of subjects: 3500
Study 1611372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for bedwetting
Number of subjects: 3500
Study 1611372 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 3500
Study 6395279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose cefoxitin
Number of subjects: 301
Study 6395279 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cefonicid
Number of subjects: 301
Study 6395279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 301
Study 30992306 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 30992306 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 30992306 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone and Naltrexone (combined)
Number of subjects: 0
Study 29577681 — intervention group
Group type: EXPERIMENTAL
Intervention: Radotinib (400 mg once daily)
Number of subjects: 0
Study 27013382 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenpep (25,000 lipase units)
Number of subjects: 96
Study 27013382 — intervention group
Group type: COMPARATOR
Intervention: Kreon (25,000 lipase units)
Number of subjects: 96
Study 24475284 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli endotoxin (lipopolysaccharide, LPS) 0.3 ng/kg at 12 noon
Number of subjects: 12
Study 24475284 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli endotoxin (lipopolysaccharide, LPS) 0.3 ng/kg at 12 midnight
Number of subjects: 12
Study 24475284 — intervention group
Group type: COMPARATOR
Intervention: Control (no endotoxin administration)
Number of subjects: 12
Study 22776778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin QD + COC QD for 21 days
Number of subjects: 20
Study 22776778 — intervention group
Group type: COMPARATOR
Intervention: COC (Ortho-Cyclen) once daily for 21 days
Number of subjects: 20
Study 21135325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 160
Study 21135325 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance antidepressant medication
Number of subjects: 160
Study 21135325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17486631 — intervention group
Group type: EXPERIMENTAL
Intervention: Defendants with mental retardation (MR) and mentally typical defendants (non-MR) instructed to fake performance on the test.
Number of subjects: 0
Study 17486631 — intervention group
Group type: COMPARATOR
Intervention: Standard conditions for MR and non-MR defendants taking the test.
Number of subjects: 0
Study 16023249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated plasma separation (FPS, Prometheus)
Number of subjects: 8
Study 16023249 — intervention group
Group type: COMPARATOR
Intervention: Albumin dialysis (AD, MARS)
Number of subjects: 8
Study 12613056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple educational interventions including two-way communications, printed and graphic materials, and locally respected health personnel as educators.
Number of subjects: 20
Study 12613056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective educational methods that can be generalized to other physician groups.
Number of subjects: 20
Study 9861123 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg kg-1 at induction of anaesthesia
Number of subjects: 0
Study 9861123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (morphine given 30 min later at skin incision)
Number of subjects: 0
Study 9243217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone-Gentamicin eye drops
Number of subjects: 112
Study 9243217 — intervention group
Group type: COMPARATOR
Intervention: Maxitrol (dexamethasone, neomycin, polymyxin B) eye drops
Number of subjects: 112
Study 2664670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative cefuroxime (1500 mg and 750 mg intravenously, followed by 750 mg every eight hours for 24 hours postoperatively)
Number of subjects: 196
Study 2664670 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cefuroxime (1500 mg and 750 mg intravenously)
Number of subjects: 196
Study 1276626 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy followed by chemotherapy
Number of subjects: 373
Study 1276626 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy restricted to the pelvic area
Number of subjects: 373
Study 1276626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 373
Study 1276626 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-abdomen irradiation
Number of subjects: 373
Study 31883418 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + axitinib
Number of subjects: 67
Study 31883418 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 67
Study 31170077 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 20 min, anodal electrode on M1 area of affected hemisphere)
Number of subjects: 40
Study 31170077 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (5 s) during wrist robotic rehabilitation training
Number of subjects: 40
Study 31170077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Real tDCS and Sham tDCS)
Number of subjects: 40
Study 31170077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of wrist robot-assisted training and tDCS
Number of subjects: 40
Study 28500815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline plus pentavalent antimony (Sbv)
Number of subjects: 164
Study 28500815 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pentavalent antimony (Sbv)
Number of subjects: 164
Study 26307212 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized interactive mobile health intervention (iSTEP)
Number of subjects: 21
Study 24064689 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly
Number of subjects: 243
Study 24064689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 21261667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (specific exercises aimed at strengthening or stretching the shoulder girdle, completed 3 days per week)
Number of subjects: 44
Study 21261667 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard instructions)
Number of subjects: 44
Study 21261667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 44
Study 21261667 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 19166975 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16940979 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic lymphadenectomy (SL)
Number of subjects: 268
Study 15116984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial mapping analogous to symbolic mapping (Experiment 1)
Number of subjects: 0
Study 15116984 — intervention group
Group type: EXPERIMENTAL
Intervention: Mappings conducive to simple transformational rules (Experiments 2 and 3)
Number of subjects: 0
Study 11277687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary individuals
Number of subjects: 1322
Study 11277687 — intervention group
Group type: EXPERIMENTAL
Intervention: Less education
Number of subjects: 1322
Study 11277687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1322
Study 11277687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmarried status
Number of subjects: 1322
Study 9237594 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP 1 day prior to surgery
Number of subjects: 52
Study 9237594 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP 1-2 h prior to CPB
Number of subjects: 52
Study 9237594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 52
Study 8513189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulguration under EMLA anaesthesia
Number of subjects: 22
Study 8513189 — intervention group
Group type: COMPARATOR
Intervention: Topical tretinoin
Number of subjects: 22
Study 8513189 — intervention group
Group type: EXPERIMENTAL
Intervention: Light electrocautery using EMLA anaesthetic
Number of subjects: 22
Study 8513189 — intervention group
Group type: COMPARATOR
Intervention: Fulguration without anaesthesia
Number of subjects: 22
Study 2446060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg) + Hydrochlorothiazide (25 mg)
Number of subjects: 35
Study 2446060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg) + Hydrochlorothiazide (12.5 mg)
Number of subjects: 35
Study 29724188 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25-50 mg/day
Number of subjects: 170
Study 29724188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 27110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg, once daily)
Number of subjects: 260
Study 27110370 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.6 mg, thrice daily)
Number of subjects: 260
Study 27110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 260
Study 27110370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 260
Study 25181763 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory‐based Internet intervention
Number of subjects: 220
Study 22430690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation technique
Number of subjects: 0
Study 22430690 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 0
Study 22430690 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step technique
Number of subjects: 0
Study 20633748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon treatment (IFA) for 24 weeks
Number of subjects: 30
Study 20633748 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 30
Study 18691996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin vs Pravastatin 20 mg
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin vs Simvastatin
Number of subjects: 2268
Study 18691996 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin vs Pravastatin
Number of subjects: 2268
Study 15777327 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene membrane only (Group 1, n=12)
Number of subjects: 62
Study 15777327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable polylactide/polyglycolide copolymer membrane only (Group 2, n=11)
Number of subjects: 62
Study 15777327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable membrane and autogenous bone graft (Group 3, n=13)
Number of subjects: 62
Study 15777327 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft only (Group 4, n=14)
Number of subjects: 62
Study 15777327 — intervention group
Group type: COMPARATOR
Intervention: No membrane and no bone graft (Group 5, n=12)
Number of subjects: 62
Study 15777327 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane use (Groups 1, 2, and 3)
Number of subjects: 62
Study 12464950 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily for 3 weeks
Number of subjects: 0
Study 12464950 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily for 6 weeks
Number of subjects: 0
Study 12464950 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/daily
Number of subjects: 0
Study 10028208 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based advocacy intervention
Number of subjects: 278
Study 10028208 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 278
Study 7573091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 40 mg methylprednisolone acetate
Number of subjects: 21
Study 7573091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 40 mg methylprednisolone acetate
Number of subjects: 21
Study 2207001 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular irradiation
Number of subjects: 246
Study 2207001 — intervention group
Group type: COMPARATOR
Intervention: No testicular irradiation (Control)
Number of subjects: 246
Study 347989 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol
Number of subjects: 11
Study 347989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30160577 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 12
Study 30160577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28369340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg)
Number of subjects: 477
Study 28369340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (pooled three highest dose arms)
Number of subjects: 477
Study 28369340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477